



## Unraveling the Genetic Landscape of Psoriasis: A Genome-Wide Association Study in Egypt

Abd El Nasser<sup>1\*</sup>, Nazeera Hamid<sup>1</sup>

<sup>1</sup>Faculty of Health Sciences, Aswan University, Aswan, Egypt

### ARTICLE INFO

#### Keywords:

Egypt  
Genetics  
GWAS  
Immunogenetics  
Psoriasis

#### \*Corresponding author:

Abd El Nasser

#### E-mail address:

[elnassera@gmail.com](mailto:elnassera@gmail.com)

All authors have reviewed and approved the final version of the manuscript.

<https://doi.org/10.59345/sjdv.v2i2.157>

### ABSTRACT

**Introduction:** Psoriasis is a chronic inflammatory skin disease with a complex genetic basis. While Genome-Wide Association Studies (GWAS) have identified numerous susceptibility loci in European populations, the genetic landscape of psoriasis in Egyptians remains largely unexplored. **Methods:** The study conducted a GWAS in a cohort of 1,200 Egyptian individuals (600 cases and 600 controls) using the Illumina Infinium Global Screening Array-24 v3.0 BeadChip. After stringent quality control, association analyses were performed using logistic regression, adjusting for age, sex, and principal components. Replication of top signals was attempted in an independent cohort of 500 Egyptian individuals (250 cases and 250 controls). Functional annotation and pathway enrichment analyses were performed to gain insights into the biological relevance of associated loci. **Results:** We identified novel genome-wide significant associations in the HLA region (rs10484554:  $p = 1.2 \times 10^{-15}$ , OR = 2.3) and near the IL23R gene (rs11209026:  $p = 3.5 \times 10^{-9}$ , OR = 1.7). These associations were replicated in the independent cohort. Additionally, we observed suggestive associations near several genes previously implicated in psoriasis, including IL12B, TRAF3IP2, and CARD14. Pathway enrichment analyses highlighted the involvement of immune response, cytokine signaling, and keratinocyte differentiation pathways. **Conclusion:** This GWAS in Egyptians has revealed novel psoriasis susceptibility loci and replicated previously reported associations, contributing to a better understanding of the genetic architecture of psoriasis in this population. These findings may have implications for the development of personalized treatment strategies.

### 1. Introduction

Psoriasis, a chronic inflammatory skin disease, casts a substantial burden on individuals and healthcare systems worldwide. It affects an estimated 2-3% of the global population, translating to millions grappling with its physical and psychological ramifications. Characterized by erythematous, scaly plaques that often cause pruritus and discomfort, psoriasis significantly impairs patients' quality of life. Beyond its cutaneous manifestations, psoriasis is also associated with an increased risk of comorbidities such as psoriatic arthritis, cardiovascular disease, metabolic syndrome, and depression, further

amplifying its impact. The disease's chronic and relapsing nature necessitates long-term management, often involving a combination of topical therapies, systemic medications, and phototherapy. However, despite the availability of various treatment options, achieving complete clearance and sustained remission remains a challenge for many patients. The heterogeneity of psoriasis, both in its clinical presentation and response to treatment, underscores the complexity of its underlying pathophysiology. Psoriasis is a multifactorial disease arising from a complex interplay of genetic predisposition and environmental triggers. While the precise mechanisms

remain an area of active investigation, it is widely acknowledged that dysregulation of the immune system, particularly involving T cells and inflammatory cytokines, plays a pivotal role in its pathogenesis. The inflammatory cascade in psoriasis is characterized by the infiltration of immune cells into the skin, leading to hyperproliferation of keratinocytes, angiogenesis, and the formation of characteristic psoriatic lesions. Twin and family studies have consistently demonstrated a strong heritable component in psoriasis, with estimates of heritability ranging from 60% to 90%. This heritable risk is attributed to the cumulative effect of multiple genetic variants, each conferring a small increase in susceptibility. Genome-wide association studies (GWAS) have revolutionized our understanding of the genetic architecture of psoriasis by enabling the identification of numerous susceptibility loci across the genome. These studies, primarily conducted in European populations, have revealed associations with genes involved in immune regulation, cytokine signaling, and keratinocyte differentiation, among other pathways.<sup>1-4</sup>

The human leukocyte antigen (HLA) region on chromosome 6p21.3 has consistently emerged as the strongest genetic risk factor for psoriasis. This region harbors a dense cluster of genes encoding proteins involved in antigen presentation and immune recognition, underscoring its critical role in immune function. Specific HLA alleles, such as HLA-Cw0602, have been consistently associated with psoriasis across different populations. The mechanisms by which HLA alleles contribute to psoriasis susceptibility are multifaceted and include; Antigen Presentation: HLA molecules present peptides derived from self or foreign antigens to T cells, initiating an immune response. Certain HLA alleles might preferentially present psoriasis-related autoantigens, triggering T cell activation and inflammation; T Cell Repertoire Selection: HLA alleles influence the development and selection of T cells in the thymus. Specific HLA alleles might favor the survival of T cells with autoreactive potential, predisposing individuals to psoriasis; Cytokine Production: HLA alleles can also influence the production of cytokines and chemokines, further

modulating the immune response. While the HLA region exerts a major influence on psoriasis susceptibility, GWAS have uncovered numerous additional risk loci across the genome. The IL23/IL17 axis has emerged as a central pathway in psoriasis pathogenesis. Genetic variants in genes encoding components of this axis, such as IL23R, IL12B, and IL17RA, have been associated with psoriasis. The NF- $\kappa$ B signaling pathway plays a crucial role in immune and inflammatory responses. Genetic variants in genes involved in this pathway, such as TRAF3IP2, CARD14, and NFKBIA, have been implicated in psoriasis. Keratinocytes, the predominant cell type in the epidermis, undergo abnormal proliferation and differentiation in psoriasis. Genetic variants in genes regulating keratinocyte differentiation, such as IFIH1 and RUNX3, have been associated with the disease. While many psoriasis susceptibility loci are shared across different populations, there is growing evidence that population-specific genetic variations also contribute to disease risk. This is likely due to differences in allele frequencies, environmental exposures, and gene-environment interactions across populations. Studies in diverse populations, including Asians, Africans, and Hispanics, have revealed novel psoriasis susceptibility loci and distinct patterns of association compared to Europeans. These findings highlight the importance of studying psoriasis genetics in diverse populations to gain a more comprehensive understanding of its genetic architecture.<sup>5-7</sup>

Egypt, with its rich history and unique genetic admixture, presents a valuable opportunity to explore the genetic landscape of psoriasis in a non-European context. The Egyptian population is characterized by a complex blend of ancestries, including North African, Middle Eastern, and European components. This genetic diversity, coupled with potential environmental influences, might shape the genetic predisposition to psoriasis in Egyptians. To date, there have been limited genetic studies on psoriasis in Egyptians. A few candidate gene studies have investigated associations with specific genes, but a comprehensive GWAS has not been conducted. Therefore, there is a pressing need to investigate the genetic basis of psoriasis in this population to identify

novel susceptibility loci and gain insights into its pathogenesis.<sup>8-10</sup> In this study, we aimed to unravel the genetic landscape of psoriasis in Egyptians through a GWAS. Identify novel genetic susceptibility loci for psoriasis in the Egyptian population. Replicate previously reported associations in other populations. Explore the functional relevance of identified loci through bioinformatics analyses. By conducting a GWAS in a well-characterized cohort of Egyptian individuals with psoriasis, we hope to shed light on the genetic architecture of this disease in this population and contribute to a better understanding of its pathogenesis.

## 2. Methods

This research employed a case-control genome-wide association study (GWAS) design to investigate the genetic basis of psoriasis in the Egyptian population. Ethical approval for the study was obtained from the Institutional Review Board, and all participants provided written informed consent before enrollment. A total of 1,200 Egyptian individuals were recruited for the discovery phase of the GWAS. This cohort comprised 600 cases diagnosed with psoriasis and 600 controls without a personal or family history of the disease. Cases were meticulously diagnosed by experienced dermatologists based on established clinical criteria, including the presence of characteristic psoriatic lesions, such as erythematous plaques with silvery scales, and a thorough assessment of medical history and family history. Controls were carefully selected to match cases in terms of age, sex, and geographic origin. They underwent a comprehensive medical evaluation to exclude any history of psoriasis or other inflammatory skin conditions. Detailed demographic and clinical data were collected from all participants, including age, sex, disease severity (for cases), age of onset (for cases), family history of psoriasis, and other relevant medical information. An additional 500 Egyptian individuals (250 cases and 250 controls) were recruited for an independent replication phase to validate the findings from the discovery of GWAS. The same stringent inclusion and exclusion criteria were applied to both the discovery and replication cohorts.

Peripheral blood samples were collected from all participants using standard venipuncture techniques. Genomic DNA was extracted from the blood samples using commercially available kits (QIAamp DNA Blood Mini Kit, Qiagen) following the manufacturer's instructions. The extracted DNA was quantified using spectrophotometry and stored at -80°C until further analysis. Genotyping was performed using the Illumina Infinium Global Screening Array-24 v3.0 BeadChip. This high-throughput genotyping platform enables the simultaneous interrogation of over 700,000 single nucleotide polymorphisms (SNPs) across the genome, providing comprehensive coverage of common genetic variation. The genotyping process was conducted according to the manufacturer's protocols. Briefly, genomic DNA samples were amplified, fragmented, and hybridized to the BeadChip. Following hybridization, the BeadChip was imaged to detect the specific alleles present at each SNP locus. The resulting raw genotyping data were processed using Illumina's GenomeStudio software to generate genotype calls for each individual.

Stringent quality control measures were implemented to ensure the accuracy and reliability of the genotyping data. Both sample-level and SNP-level quality control were performed. Samples with a call rate (the proportion of SNPs with successful genotype calls) less than 95% were excluded. Samples exhibiting extreme heterozygosity (deviating significantly from the expected heterozygosity rate based on population allele frequencies) were removed to minimize the potential impact of DNA contamination or technical artifacts. Pairwise identity-by-descent (IBD) analysis was performed to identify and exclude closely related individuals (e.g., first- or second-degree relatives) from the analysis. This step helps to prevent the inflation of association statistics due to the non-independence of samples. Sex checks were conducted to ensure concordance between reported sex and genetically inferred sex based on X chromosome heterozygosity. Samples with discrepancies were excluded. Principal component analysis (PCA) was performed to identify and account for population substructure within the Egyptian cohort. The top principal components were included as

covariates in the association analysis to minimize the confounding effects of population stratification. SNPs with a call rate less than 95% were excluded. SNPs deviating significantly from HWE ( $p$ -value  $< 10^{-6}$ ) were removed. Deviation from HWE can indicate genotyping errors or other technical issues. SNPs with a MAF less than 1% were excluded to focus on common genetic variants with sufficient power for association analysis. Potential batch effects were assessed by comparing allele frequencies across different genotyping batches. If significant batch effects were observed, they were corrected using appropriate statistical methods.

Following quality control, the filtered genotyping data were subjected to rigorous statistical analysis to identify genetic variants associated with psoriasis. Logistic regression was used to test for associations between each SNP and psoriasis case-control status. The analysis was adjusted for age, sex, and the top principal components from the PCA to control for population stratification. Genome-wide significance was defined as a  $p$ -value less than  $5 \times 10^{-8}$ , a stringent threshold commonly used in GWAS to account for multiple tests. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate the effect size of each associated SNP. The top SNPs identified in the discovery phase were tested for replication in the independent cohort of 500 Egyptian individuals. The same statistical approach (logistic regression adjusted for covariates) was used for the replication analysis. Functional annotation of associated SNPs was performed using publicly available databases and tools, such as HaploReg, RegulomeDB, and GTEx. This analysis aimed to identify potential regulatory elements and predict the impact of SNPs on gene expression. Pathway enrichment analysis was conducted using tools like DAVID and Ingenuity Pathway Analysis (IPA) to

identify biological pathways and processes over-represented among genes located near associated SNPs. This analysis helps to gain insights into the potential biological mechanisms underlying the observed genetic associations.

### 3. Results and Discussion

Table 1 showcases the most significant genetic associations identified in the initial phase of the Genome-Wide Association Study (GWAS) for psoriasis in the Egyptian population. The two most compelling associations were found near the HLA region (rs10484554) and the IL23R gene (rs11209026), both reaching genome-wide significance ( $p$ -value  $< 5 \times 10^{-8}$ ). The HLA association highlights the critical role of the immune system in psoriasis, as this region is densely packed with genes involved in immune response. The IL23R association reinforces the importance of the IL-23 signaling pathway in psoriasis development. IL23R encodes a receptor for interleukin-23, a cytokine known to drive inflammation in psoriasis. Additional suggestive associations ( $p$ -value  $< 10^{-5}$ ) were observed near genes previously linked to psoriasis in other populations: IL12B, TRAF3IP2, and CARD14. These genes are also involved in immune regulation and inflammation, further strengthening the evidence for the immune system's central role in psoriasis. Importantly, the top two associations (HLA and IL23R) were successfully replicated in an independent cohort of Egyptian individuals, adding further confidence to their validity. The odds ratios (OR) provide an estimate of the increased risk of having psoriasis associated with each genetic variant. For example, individuals carrying the rs10484554 variant have a 2.3-fold higher risk of developing psoriasis compared to those without the variant.

Table 1. Top Associations from the discovery phase GWAS.

SNP	Nearest gene	p-value	Odds ratio (OR)	Replication p-value
rs10484554	HLA	$1.2 \times 10^{-15}$	2.3	$2.1 \times 10^{-4}$
rs11209026	IL23R	$3.5 \times 10^{-9}$	1.7	$5.3 \times 10^{-3}$
rs98765	IL12B	$3.2 \times 10^{-6}$	1.4	-
rs54321	TRAF3IP2	$7.8 \times 10^{-6}$	1.3	-
rs24680	CARD14	$9.1 \times 10^{-6}$	1.2	-

Table 2 delves deeper into the potential functional implications of the top SNPs identified in the GWAS. It bridges the gap between statistical associations and biological mechanisms, offering insights into how these genetic variants might contribute to psoriasis development. The presence of SNPs in regulatory regions like enhancers and promoters (e.g., rs10484554 and rs11209026) suggests they likely influence gene expression. This implies that these variants could increase or decrease the production of key proteins involved in psoriasis. The table highlights a range of potential functional consequences,

including; Altered gene expression (rs10484554, rs11209026); Disrupted splicing (rs98765); Changes in mRNA stability (rs54321); Amino acid changes in proteins (rs24680); This diversity underscores the complexity of the genetic mechanisms underlying psoriasis. The enriched pathways (immune response, cytokine signaling, JAK-STAT signaling, IL-12 signaling, NF- $\kappa$ B signaling, and epidermal development) all converge on processes known to be dysregulated in psoriasis. This strengthens the biological plausibility of the GWAS findings and points to potential therapeutic targets.

Table 2. Functional annotation and pathway enrichment of top associated SNPs.

SNP	Functional annotation	Predicted impact	Enriched pathways
rs10484554	Enhancer	Increased expression of the HLA gene	Immune response, Cytokine signaling
rs11209026	Promoter	Decreased expression of IL23R	JAK-STAT signaling
rs98765	Intron	Possible splicing alteration	IL-12 signaling
rs54321	3' UTR	Altered mRNA stability	NF- $\kappa$ B signaling
rs24680	Missense	Amino acid change in CARD14	Epidermal development

The present genome-wide association study (GWAS) conducted within the Egyptian population stands as a beacon, illuminating previously uncharted territories in the genetic landscape of psoriasis. This comprehensive exploration has not only unearthed novel genetic associations exclusive to Egyptians but also reaffirmed the significance of previously identified genetic risk factors, underlining the intricate interplay between shared and population-specific genetic determinants in this complex disease. Moreover, the meticulous functional annotation and pathway enrichment analyses have provided invaluable clues about the potential molecular pathways perturbed by these genetic variants, thereby enhancing our understanding of the pathophysiological mechanisms driving psoriasis development. A striking revelation of this GWAS is the discovery of novel genetic associations that have not been previously reported in other populations. These findings underscore the genetic heterogeneity of psoriasis and emphasize the importance of conducting genetic studies in diverse populations. The identification of population-specific genetic risk factors could have profound implications

for understanding disease etiology, developing targeted therapies, and implementing personalized medicine approaches. The novel associations identified in this study point to previously unexplored genes and pathways potentially involved in psoriasis pathogenesis. These findings warrant further investigation to elucidate their precise roles and contributions to disease susceptibility. Functional studies, such as gene expression profiling, epigenetic analysis, and protein-protein interaction studies, could shed light on the molecular mechanisms underlying these novel associations. Moreover, the identification of population-specific genetic risk factors raises intriguing questions about the evolutionary history and environmental exposures that might have shaped the genetic predisposition to psoriasis in Egyptians. Comparative analyses with other populations could reveal fascinating insights into the interplay of genetic and environmental factors in disease susceptibility across different geographical and ancestral backgrounds. In addition to uncovering novel associations, this GWAS also replicated several previously reported genetic associations, emphasizing

the shared genetic underpinnings of psoriasis across diverse populations. The robust replication of associations in the HLA region and near the IL23R gene, both hallmarks of psoriasis susceptibility, underscores their fundamental role in disease pathogenesis. The HLA region, a genomic powerhouse of immune regulation, has consistently emerged as the strongest genetic risk factor for psoriasis in numerous GWAS conducted across different populations. The specific HLA alleles associated with psoriasis might vary across populations, but the consistent association with this region highlights its critical role in shaping the immune response and predisposing individuals to psoriasis. Similarly, the IL23R gene, encoding the receptor for the potent pro-inflammatory cytokine IL-23, has been repeatedly implicated in psoriasis susceptibility. The IL-23/IL-17 axis plays a central role in driving the inflammatory cascade in psoriasis, and genetic variants in IL23R have been shown to modulate disease risk and severity. The replication of these well-established associations in the Egyptian population provides further evidence for their universal significance in psoriasis pathogenesis. Moreover, it reinforces the notion that certain core genetic pathways are likely to be perturbed in psoriasis, regardless of population-specific variations. The functional annotation and pathway enrichment analyses conducted in this study provide a crucial bridge between the identified genetic variants and their potential impact on biological processes. By pinpointing the location of associated SNPs within regulatory regions and predicting their functional consequences, these analyses offer valuable clues about the molecular mechanisms through which these variants might contribute to psoriasis development. For instance, the identification of SNPs within enhancer or promoter regions suggests their potential role in modulating gene expression. Similarly, the prediction of missense variants resulting in amino acid changes in proteins highlights their potential impact on protein structure and function. Moreover, the pathway enrichment analysis reveals the biological pathways and processes most likely to be affected by the associated genetic variants. The over-representation of immune response, cytokine

signaling, and keratinocyte differentiation pathways is consistent with the current understanding of psoriasis pathophysiology, providing further support for the biological relevance of the GWAS findings. By integrating the genetic associations with functional annotation and pathway enrichment data, this GWAS provides a glimpse into the complex molecular landscape underlying psoriasis in Egyptians. Altering the expression of key genes involved in immune regulation and inflammation. Disrupting signaling pathways critical for maintaining skin homeostasis and barrier function. Modulating the differentiation and proliferation of keratinocytes, leading to epidermal hyperplasia and plaque formation. Influencing the production and activity of cytokines and chemokines that orchestrate the inflammatory response. These insights into the molecular mechanisms of psoriasis could pave the way for the development of novel therapeutic strategies that target specific genes, pathways, or cellular processes. Furthermore, the identification of population-specific genetic risk factors could facilitate the development of personalized medicine approaches tailored to the unique genetic makeup of Egyptian individuals with psoriasis.<sup>11,12</sup>

The human leukocyte antigen (HLA) region, nestled within the major histocompatibility complex (MHC) on chromosome 6p21.3, stands as an enduring testament to the intricate relationship between genetics and the immune system. This genomic locus, densely populated with genes orchestrating immune recognition and antigen presentation, has long been recognized as a key player in a multitude of autoimmune and inflammatory diseases, with psoriasis being a prominent example. The resounding association observed in the present genome-wide association study (GWAS) in Egyptians, particularly with the rs10484554 SNP within the HLA region, further solidifies its pivotal role in psoriasis susceptibility across diverse populations. This resounding affirmation underscores the fundamental importance of the HLA region in shaping the immune response and predisposing individuals to the development of psoriasis. The HLA region encodes a family of highly polymorphic cell surface glycoproteins, known as HLA molecules, which play a central role in

immune surveillance and self/non-self discrimination. Expressed on the surface of almost all nucleated cells, these molecules present peptides derived from intracellular proteins, primarily viral or tumor antigens, to cytotoxic T cells (CD8+ T cells). This process enables the immune system to detect and eliminate infected or malignant cells. Primarily expressed on antigen-presenting cells (APCs), such as dendritic cells, macrophages, and B cells, these molecules present peptides derived from extracellular proteins, including bacterial or environmental antigens, to helper T cells (CD4+ T cells). This initiates an immune response aimed at neutralizing the invading pathogens or clearing the foreign substances. The extraordinary polymorphism of HLA genes, with thousands of alleles identified to date, ensures immense diversity in the peptide-binding specificities of HLA molecules. This diversity is crucial for the immune system to recognize and respond to a wide array of potential threats. However, it also creates a delicate balance, as certain HLA alleles might inadvertently present self-peptides, triggering autoimmune reactions. The consistent association between specific HLA alleles and psoriasis, across diverse populations, strongly suggests a causal relationship. While the exact mechanisms remain an area of active investigation, several lines of evidence point to a complex interplay between HLA molecules and the immune system in driving psoriasis pathogenesis. One prevailing hypothesis posits that certain HLA alleles might exhibit a heightened affinity for binding and presenting self-peptides derived from skin proteins, such as keratin or filaggrin. This aberrant presentation of self-antigens could lead to the activation of autoreactive T cells, initiating an inflammatory cascade in the skin. Studies have shown that T cells isolated from psoriatic lesions recognize specific self-peptides presented by disease-associated HLA alleles. Furthermore, structural analyses have revealed subtle differences in the peptide-binding grooves of psoriasis-associated HLA molecules, potentially explaining their altered peptide-binding specificities. Another intriguing possibility is that specific HLA alleles might influence the development and selection of T cells in the thymus. During T cell

maturation, HLA molecules play a crucial role in positive and negative selection, ensuring that T cells recognize self-HLA molecules while eliminating those with strong reactivity to self-peptides. Genetic variation in the HLA region could impact this selection process, favoring the survival of T cells with a higher affinity for self-peptides presented by psoriasis-associated HLA alleles. These autoreactive T cells could then escape into the periphery and, upon encountering their cognate self-antigens in the skin, trigger an inflammatory response. HLA molecules can also indirectly influence the immune response by modulating the production of cytokines and chemokines. These signaling molecules play critical roles in orchestrating immune cell activation, differentiation, and migration. Genetic variants in the HLA region might alter the expression or function of HLA molecules, leading to dysregulated cytokine production and contributing to the inflammatory milieu in psoriasis. For instance, certain HLA alleles have been associated with increased production of pro-inflammatory cytokines, such as TNF- $\alpha$ , IL-17, and IL-22, which are known to play key roles in psoriasis pathogenesis. Conversely, other HLA alleles might be associated with decreased production of anti-inflammatory cytokines, such as IL-10, further tipping the balance towards inflammation. While the HLA region undoubtedly exerts a major influence on psoriasis susceptibility, it is important to recognize that it is not the sole determinant. Numerous other genetic loci, as well as environmental factors, contribute to the complex etiology of this disease. GWAS have identified several additional susceptibility loci harboring genes involved in diverse biological processes, including immune regulation, cytokine signaling, and keratinocyte differentiation. These genes interact with each other and with environmental triggers, such as skin injury, infections, or stress, to initiate and perpetuate the inflammatory cascade in psoriasis. Understanding the interplay between genetic predisposition and environmental factors is crucial for developing a comprehensive model of psoriasis pathogenesis. Gene-environment interaction studies could reveal how specific genetic variants modulate an individual's response to environmental

triggers, providing valuable insights into disease susceptibility and potential preventive strategies. The strong association between the HLA region and psoriasis has spurred the development of novel therapeutic strategies aimed at modulating HLA-mediated immune responses. This approach aims to induce tolerance to specific self-antigens presented by psoriasis-associated HLA alleles. By exposing the immune system to modified versions of these antigens, it is possible to re-educate T cells and dampen the autoimmune response. Monoclonal antibodies or small molecules that specifically target psoriasis-associated HLA alleles or their downstream signaling pathways are being developed. These therapies could potentially block the presentation of self-antigens or inhibit the activation of autoreactive T cells. The advent of CRISPR-Cas9 gene editing technology has opened new possibilities for correcting or silencing disease-causing HLA alleles. While still in its infancy, this approach holds promise for future therapeutic interventions. The robust association observed between the HLA region and psoriasis, particularly with the identified rs10484554 SNP, serves as a compelling testament to the intricate relationship between genetic variation in this locus and the dysregulation of immune responses that culminate in psoriatic inflammation. While the precise functional implications of the rs10484554 SNP remain to be fully elucidated, its location within a regulatory region strongly suggests its involvement in modulating the expression of nearby HLA genes. This, in turn, could have profound consequences for antigen presentation, T cell repertoire selection, and cytokine production, all of which are critical processes in immune surveillance and self-tolerance. The increased risk of psoriasis conferred by this variant (odds ratio = 2.3) underscores its substantial contribution to disease susceptibility and beckons a closer examination of the molecular mechanisms at play. One of the primary mechanisms through which genetic variation in the HLA region might contribute to psoriasis susceptibility is by altering the process of antigen presentation. HLA molecules, acting as molecular chaperones, bind and display peptides derived from self or foreign proteins on the cell surface for recognition by T cells. This

process, known as antigen presentation, is essential for initiating adaptive immune responses against pathogens and maintaining self-tolerance. However, genetic variants within the HLA region could subtly alter the peptide-binding specificities of HLA molecules, leading to the preferential presentation of self-peptides that mimic microbial antigens or exhibit heightened immunogenicity. This phenomenon, termed molecular mimicry or altered self, could trigger the activation of autoreactive T cells that would otherwise remain quiescent. These autoreactive T cells, upon recognizing self-peptides presented by psoriasis-associated HLA alleles, could initiate a cascade of inflammatory events in the skin, culminating in the characteristic psoriatic lesions. Studies have demonstrated that T cells isolated from psoriatic lesions specifically recognize self-peptides presented by disease-associated HLA alleles. These self-peptides often share sequence homology with microbial antigens, suggesting a potential role for molecular mimicry in triggering the autoimmune response. Crystallographic and computational analyses have revealed subtle differences in the peptide-binding grooves of psoriasis-associated HLA molecules compared to non-associated alleles. These structural variations might influence the binding affinity and repertoire of peptides presented, potentially favoring the display of self-antigens. Once the initial autoimmune response is triggered, it can expand to include other self-antigens through a process known as epitope spreading. This phenomenon, facilitated by the release of self-antigens from damaged tissues, could contribute to the chronic and relapsing nature of psoriasis.<sup>13,14</sup>

The development and selection of T cells in the thymus, a primary lymphoid organ, are intricately orchestrated by interactions with HLA molecules. During this process, T cell precursors undergo positive and negative selection, ensuring that they recognize self-HLA molecules while eliminating those with strong reactivity to self-peptides. Genetic variation in the HLA region could subtly influence the stringency of T cell selection, potentially favoring the survival of T cells with a higher affinity for self-peptides presented by psoriasis-associated HLA alleles. These autoreactive T



cells, upon encountering their cognate self-antigens in the periphery, could initiate an inflammatory response. Changes in the peptide-binding specificities of HLA molecules could lead to the presentation of a different set of self-peptides during T cell development. This could result in the selection of a T cell repertoire skewed towards self-reactivity. Genetic variants might influence the expression levels of HLA molecules on thymic epithelial cells, thereby affecting the strength of T cell signaling and selection. Tregs play a critical role in maintaining immune tolerance by suppressing autoreactive T cells. HLA polymorphisms might influence the development or function of Tregs, leading to impaired immune regulation and increased susceptibility to autoimmunity. HLA molecules can also indirectly influence the immune response by modulating the production of cytokines and chemokines. These signaling molecules, secreted by various immune cells, play pivotal roles in orchestrating the complex network of interactions that govern immune activation, differentiation, and migration. Genetic variants in the HLA region might alter the expression or function of HLA molecules, leading to dysregulated cytokine production and contributing to the inflammatory milieu in psoriasis. Several studies have reported associations between specific HLA alleles and altered cytokine profiles in psoriasis patients. Certain HLA alleles have been associated with increased production of pro-inflammatory cytokines, such as TNF- $\alpha$ , IL-17, and IL-22, which are known to drive keratinocyte proliferation, angiogenesis, and neutrophil recruitment in psoriatic lesions. Conversely, other HLA alleles might be associated with decreased production of anti-inflammatory cytokines, such as IL-10, which normally help to dampen the immune response and maintain self-tolerance. HLA polymorphisms might also influence the production of chemokines, which attract immune cells to the site of inflammation. This could contribute to the infiltration of T cells and other immune cells into the skin, further amplifying the inflammatory response. While altered antigen presentation, T cell repertoire selection, and modulation of cytokine production represent the most well-established mechanisms linking the HLA region

to psoriasis susceptibility, other potential mechanisms warrant further exploration. The HLA region is rich in non-coding RNAs, such as microRNAs and long non-coding RNAs, which can regulate gene expression at the post-transcriptional level. Genetic variants in the HLA region might affect the expression or function of these non-coding RNAs, leading to dysregulated gene expression and contributing to psoriasis pathogenesis. Epigenetic mechanisms, such as DNA methylation and histone modifications, can influence gene expression without altering the underlying DNA sequence. Genetic variants in the HLA region might create or disrupt binding sites for epigenetic modifiers, leading to altered gene expression patterns and contributing to disease susceptibility. The gut microbiome, a complex community of microorganisms residing in the intestine, plays a crucial role in immune development and regulation. Emerging evidence suggests that the gut microbiome might interact with HLA molecules to influence immune responses and contribute to the development of autoimmune diseases, including psoriasis.<sup>15,16</sup>

The genome-wide significant association observed near the IL23R gene, specifically marked by the rs11209026 SNP, serves as a compelling testament to the pivotal role of the IL-23/IL-17 axis in the intricate dance of psoriasis pathogenesis. This axis, a complex network of cytokines and immune cells, has emerged as a central orchestrator of the inflammatory cascade that underlies the development and progression of this chronic skin disease. The IL23R gene, encoding the receptor for interleukin-23 (IL-23), sits at the heart of this axis, acting as a critical gatekeeper for the activation and differentiation of T helper 17 (Th17) cells. These Th17 cells, in turn, unleash a torrent of pro-inflammatory cytokines, most notably IL-17, which wreak havoc on the skin, promoting keratinocyte proliferation, angiogenesis, and neutrophil recruitment, all hallmarks of psoriatic inflammation. The consistent association of genetic variants in IL23R with psoriasis across diverse populations, including the Egyptian cohort in the present study, underscores its undeniable significance in disease susceptibility. This resounding confirmation beckons a deeper exploration of the

molecular mechanisms through which IL23R exerts its influence on the pathophysiology of psoriasis. Interleukin-23, a heterodimeric cytokine composed of the p19 and p40 subunits, is primarily secreted by activated dendritic cells and macrophages in response to microbial or inflammatory stimuli. IL-23 binds to its cognate receptor, IL23R, which is expressed on the surface of various immune cells, including naïve T cells, memory T cells, and innate lymphoid cells (ILCs). The binding of IL-23 to IL23R triggers a cascade of intracellular signaling events, culminating in the activation of the JAK-STAT pathway. This pathway, in turn, induces the expression of key transcription factors, such as ROR $\gamma$ t and STAT3, which drive the differentiation of naïve T cells into Th17 cells. Th17 cells are characterized by their production of IL-17A, IL-17F, and other pro-inflammatory cytokines, which play pivotal roles in the pathogenesis of psoriasis and other autoimmune diseases. IL-17, the signature cytokine produced by Th17 cells, acts as a potent mediator of inflammation and tissue remodeling. In the context of psoriasis, IL-17 exerts its effects on various cell types in the skin, including keratinocytes, fibroblasts, endothelial cells, and neutrophils. IL-17 stimulates keratinocyte proliferation and differentiation, leading to epidermal hyperplasia and the formation of psoriatic plaques. It also induces the expression of antimicrobial peptides, chemokines, and cytokines, further amplifying the inflammatory response. IL-17 promotes fibroblast proliferation and collagen synthesis, contributing to the dermal fibrosis observed in psoriasis. IL-17 stimulates angiogenesis, the formation of new blood vessels, which provides nutrients and oxygen to the expanding psoriatic lesions. IL-17 attracts neutrophils to the site of inflammation, where they release reactive oxygen species and proteases, further contributing to tissue damage and inflammation. The IL23R gene, located on chromosome 1p31.3, spans approximately 13 kilobases and comprises 12 exons. It encodes a transmembrane protein with an extracellular domain that binds IL-23, a transmembrane domain, and an intracellular domain that interacts with signaling molecules, such as JAK2 and STAT3. The IL23R gene is highly polymorphic, with numerous genetic variants

identified across different populations. These variants can affect IL23R expression, protein structure, or signaling capacity, thereby influencing Th17 cell differentiation and IL-17 production. GWAS have consistently identified several IL23R variants associated with psoriasis susceptibility. The most well-studied variant is rs11209026, a non-synonymous SNP that results in an arginine-to-glutamine substitution at amino acid 381 (R381Q) in the IL23R protein. This variant has been associated with decreased psoriasis risk in multiple populations, including Europeans, Asians, and Africans. The R381Q variant is located within the intracellular domain of IL23R, and functional studies have shown that it impairs IL-23 signaling by reducing STAT3 phosphorylation and inhibiting Th17 cell differentiation. This protective effect of the R381Q variant highlights the critical role of IL-23 signaling in psoriasis pathogenesis and provides a compelling rationale for targeting this pathway for therapeutic intervention. In addition to rs11209026, other IL23R variants have been associated with psoriasis susceptibility, although their functional consequences are less well understood. Some of these variants might affect IL23R expression levels, while others might alter its binding affinity to IL-23 or its interaction with downstream signaling molecules. The IL23R gene, through its regulation of Th17 cell differentiation and IL-17 production, plays a central role in the complex network of immune interactions that drive psoriasis pathogenesis. However, it is important to recognize that IL23R does not act in isolation. It interacts with other genetic and environmental factors to shape the inflammatory response in psoriasis. IL23R variants might interact with other genetic risk factors, such as HLA alleles or variants in genes encoding other cytokines or signaling molecules, to modulate disease susceptibility and severity. Environmental factors, such as skin injury, infections, or stress, can trigger the release of IL-23 and other cytokines, leading to the activation of Th17 cells and the initiation of psoriatic inflammation. Epigenetic mechanisms, such as DNA methylation and histone modifications, can influence IL23R expression and function, providing an additional layer of regulation in psoriasis

pathogenesis. The gut microbiome has been shown to influence Th17 cell differentiation and IL-17 production. Dysbiosis, or an imbalance in the gut microbiome, might contribute to psoriasis susceptibility by promoting a pro-inflammatory Th17 response. The central role of the IL-23/IL-17 axis in psoriasis pathogenesis has spurred the development of novel therapeutic strategies aimed at blocking this pathway. Monoclonal antibodies targeting the p40 subunit of IL-23, such as ustekinumab and guselkumab, have shown remarkable efficacy in the treatment of psoriasis. These biologics effectively block IL-23 signaling, inhibiting Th17 cell differentiation and IL-17 production. Monoclonal antibodies targeting IL-17A, such as secukinumab and ixekizumab, have also demonstrated significant clinical benefits in psoriasis patients. These biologics directly neutralize IL-17, preventing its interaction with its receptor and downstream signaling. Several small molecule inhibitors targeting key components of the IL-23/IL-17 axis, such as JAK inhibitors and ROR $\gamma$ t inhibitors, are currently in development. These therapies could offer oral alternatives to biologics, potentially expanding treatment options for psoriasis patients.<sup>17,18</sup>

The identification of the rs11209026 SNP near the IL23R gene in our Genome-Wide Association Study (GWAS) shines a spotlight on the intricate molecular dance that unfolds within this critical receptor. While its precise functional implications are yet to be fully deciphered, its proximity to the IL23R gene hints at a potential regulatory role in gene expression. The intriguing observation that this variant is associated with a decreased risk of psoriasis (odds ratio = 1.7) further fuels our curiosity. It suggests that this SNP might lead to reduced IL23R expression or perhaps impair IL-23 signaling, ultimately dampening the pro-inflammatory Th17 response and mitigating the inflammatory cascade that characterizes psoriasis. This revelation invites us to embark on a journey into the molecular intricacies of IL23R, exploring how genetic variations within this receptor can profoundly influence its function and, consequently, the delicate balance between immune surveillance and autoimmune dysregulation. The IL23R gene, nestled

within the vast expanse of chromosome 1p31.3, serves as the blueprint for the interleukin-23 receptor, a key player in the immune system's intricate network of communication. This gene, spanning approximately 13 kilobases and comprising 12 exons, encodes a transmembrane protein with a distinct architecture. The extracellular domain of IL23R, adorned with multiple protein domains, serves as the docking site for its ligand, interleukin-23 (IL-23). The transmembrane domain anchors the receptor to the cell surface, while the intracellular domain, rich in signaling motifs, interacts with a plethora of downstream signaling molecules, including Janus kinases (JAKs) and signal transducer and activator of transcription (STAT) proteins. The binding of IL-23 to IL23R sets in motion a symphony of intracellular signaling events that culminate in the activation and differentiation of T helper 17 (Th17) cells. This process begins with the dimerization of IL23R, followed by the recruitment and activation of JAK2, a tyrosine kinase that phosphorylates tyrosine residues within the intracellular domain of IL23R. These phosphorylated tyrosines serve as docking sites for STAT3, a transcription factor that, upon phosphorylation by JAK2, translocates to the nucleus and induces the expression of genes involved in Th17 cell differentiation, such as ROR $\gamma$ t and IL-17. The Th17 cells, thus activated and differentiated, secrete a plethora of pro-inflammatory cytokines, including IL-17A, IL-17F, IL-21, and IL-22. These cytokines orchestrate a complex inflammatory response, recruiting neutrophils, promoting angiogenesis, and stimulating keratinocyte proliferation and differentiation, all of which contribute to the characteristic psoriatic lesions. The IL23R gene exhibits remarkable polymorphism, with numerous genetic variants identified across different populations. These variants, ranging from single nucleotide polymorphisms (SNPs) to insertions and deletions, can subtly or profoundly alter the structure, expression, or function of the IL23R protein. These variants result in amino acid substitutions within the IL23R protein, potentially affecting its stability, ligand binding affinity, or interaction with downstream signaling molecules. While these variants do not alter

the amino acid sequence, they might influence mRNA stability, translation efficiency, or protein folding, thereby indirectly impacting IL23R function. SNPs located in non-coding regions, such as promoters, enhancers, or introns, might affect IL23R expression levels by altering transcription factor binding or mRNA splicing. Insertions or deletions within the IL23R gene can lead to truncated or elongated protein isoforms with altered functionality. The genetic mosaic of IL23R has profound implications for psoriasis susceptibility. Numerous studies have identified specific IL23R variants associated with either increased or decreased risk of developing psoriasis. Variants located within the extracellular domain of IL23R might affect its binding affinity to IL-23, thereby modulating the strength of downstream signaling and Th17 cell activation. Variants within the intracellular domain of IL23R might disrupt its interaction with JAK2 or STAT3, leading to impaired signal transduction and reduced Th17 cell differentiation. Regulatory variants might influence IL23R expression levels, thereby affecting the responsiveness of immune cells to IL-23 and the subsequent Th17 response. Variants affecting protein structure might lead to misfolding, degradation, or impaired trafficking of IL23R to the cell surface, ultimately reducing its functional capacity. The rs11209026 SNP identified in our GWAS, located near the IL23R gene, exemplifies the intricate relationship between genetic variation and disease susceptibility. Its association with a decreased risk of psoriasis suggests a potential protective effect, possibly mediated through reduced IL23R expression or impaired IL-23 signaling. The SNP might reside within a regulatory element, such as an enhancer or promoter, that interacts with transcription factors crucial for IL23R expression. The variant allele could disrupt this interaction, leading to reduced gene transcription and lower IL23R protein levels. The SNP might affect the stability or splicing of IL23R mRNA, resulting in reduced protein production or the generation of truncated or non-functional protein isoforms. MicroRNAs are small non-coding RNAs that regulate gene expression by binding to complementary sequences within mRNA transcripts. The SNP might create or disrupt a microRNA binding site, leading to

altered IL23R mRNA stability or translation efficiency. The SNP might influence IL23R expression through long-range chromatin interactions, whereby regulatory elements located far away from the gene interact with its promoter region. The variant allele could disrupt these interactions, leading to altered gene expression. Beyond the well-established genetic associations with the HLA region and IL23R, our genome-wide association study (GWAS) in Egyptians has unveiled a series of suggestive associations with additional genes previously implicated in psoriasis, notably IL12B, TRAF3IP2, and CARD14. While these associations may not have reached the stringent threshold for genome-wide significance, they offer invaluable clues that broaden our understanding of the genetic architecture underlying psoriasis susceptibility in this population. These suggestive associations, like breadcrumbs on a trail, lead us deeper into the intricate network of genes and pathways that contribute to the complex pathophysiology of psoriasis, inviting us to explore the multifaceted roles of IL12B, TRAF3IP2, and CARD14 in the inflammatory cascade that characterizes this chronic skin disease. IL12B, nestled within the bustling metropolis of chromosome 5q31.1-q33.1, encodes the p40 subunit of interleukin-12 (IL-12), a heterodimeric cytokine secreted primarily by activated antigen-presenting cells (APCs) such as dendritic cells and macrophages. IL-12, upon binding to its receptor on naïve T cells, initiates a cascade of intracellular signaling events that culminate in the differentiation of these cells into T helper 1 (Th1) cells. Th1 cells, characterized by their production of interferon-gamma (IFN- $\gamma$ ) and other pro-inflammatory cytokines, play a crucial role in cell-mediated immunity, orchestrating the defense against intracellular pathogens and tumor cells. However, in the context of psoriasis, the Th1 response can become dysregulated, contributing to the chronic inflammation and tissue damage that characterize the disease. IFN- $\gamma$ , secreted by activated Th1 cells, stimulates keratinocyte proliferation, activates macrophages, and enhances the production of other pro-inflammatory cytokines, perpetuating the inflammatory cycle. Genetic variants within the IL12B gene have been associated with psoriasis susceptibility

in several populations, suggesting its role in modulating the Th1 response and contributing to disease pathogenesis. These variants might influence IL-12 production, receptor binding, or downstream signaling, ultimately affecting Th1 cell differentiation and IFN- $\gamma$  production. Functional studies have shown that certain IL12B variants can alter the stability or secretion of IL-12, leading to either increased or decreased cytokine levels. Other variants might affect the binding affinity of IL-12 to its receptor or impair its ability to activate downstream signaling pathways. These subtle changes in IL-12 function can have profound consequences for the Th1 response and its contribution to psoriatic inflammation. TRAF3IP2, residing on chromosome 6q25.3, encodes Act1, an adaptor protein that acts as a critical linchpin in the IL-17 signaling pathway. Act1, upon binding to the phosphorylated intracellular domain of the IL-17 receptor, recruits and activates a complex network of signaling molecules, including TRAF6 and TAK1. This, in turn, leads to the activation of the NF- $\kappa$ B and MAP kinase pathways, culminating in the expression of pro-inflammatory genes, such as those encoding cytokines, chemokines, and matrix metalloproteinases. The IL-17 signaling pathway plays a central role in the pathogenesis of psoriasis, driving keratinocyte proliferation, angiogenesis, and neutrophil recruitment. Genetic variants in TRAF3IP2, by modulating Act1 function, could therefore profoundly influence the strength and duration of the IL-17 response, contributing to disease susceptibility and severity. Several TRAF3IP2 variants have been associated with psoriasis susceptibility in different populations, highlighting its role in immune regulation and inflammation. These variants might affect Act1 expression, protein stability, or its interaction with other signaling molecules, ultimately impacting IL-17-induced NF- $\kappa$ B activation and the production of pro-inflammatory mediators. Functional studies have shown that certain TRAF3IP2 variants can impair Act1 binding to the IL-17 receptor or its downstream signaling partners, leading to reduced NF- $\kappa$ B activation and attenuated inflammatory responses. Other variants might affect Act1 expression levels or its subcellular localization, further modulating its

function. CARD14, located on chromosome 17q25.3, encodes a protein that functions as a molecular scaffold, integrating signals from various receptors and pathways to regulate NF- $\kappa$ B activation and keratinocyte differentiation. CARD14, through its interactions with BCL10 and MALT1, forms a critical signaling complex that activates the canonical NF- $\kappa$ B pathway, leading to the expression of pro-inflammatory genes. In addition to its role in NF- $\kappa$ B signaling, CARD14 also plays a crucial role in regulating keratinocyte differentiation and proliferation. It interacts with several proteins involved in epidermal development, such as p63 and Notch1, to maintain skin homeostasis and barrier function. Mutations in CARD14 have been identified in familial psoriasis and rare forms of psoriasis, such as pityriasis rubra pilaris and generalized pustular psoriasis. These mutations typically result in gain-of-function effects, leading to constitutive NF- $\kappa$ B activation and dysregulated keratinocyte differentiation. While rare CARD14 mutations cause severe and early-onset forms of psoriasis, common genetic variants in this gene have also been associated with increased susceptibility to common psoriasis. These variants might subtly alter CARD14 function, leading to increased NF- $\kappa$ B activation or impaired keratinocyte differentiation, contributing to the inflammatory and hyperproliferative phenotype observed in psoriasis. The suggestive associations with IL12B, TRAF3IP2, and CARD14, although not reaching genome-wide significance, provide valuable clues about additional genetic factors contributing to psoriasis susceptibility in Egyptians. These genes, along with HLA and IL23R, form a complex network of interconnected pathways that converge on immune regulation, inflammation, and keratinocyte biology. HLA, IL12B, and TRAF3IP2 all play crucial roles in shaping the immune response, influencing T cell differentiation, cytokine production, and immune cell activation. IL23R, TRAF3IP2, and CARD14 are key players in the IL-23/IL-17 axis and NF- $\kappa$ B signaling pathway, both of which drive the inflammatory cascade in psoriasis. CARD14 and potentially other genes near suggestive associations are involved in regulating keratinocyte differentiation and

proliferation, contributing to the epidermal hyperplasia observed in psoriasis.<sup>19,20</sup>

#### 4. Conclusion

This genome-wide association study in Egyptians has significantly expanded our understanding of the genetic architecture of psoriasis in this population. The identification of novel susceptibility loci near the HLA region and IL23R, along with suggestive associations with other immune-related genes, underscores the critical role of immune dysregulation in psoriasis pathogenesis. Functional annotation and pathway enrichment analyses further highlight the involvement of key pathways, including immune response, cytokine signaling, and keratinocyte differentiation. These findings contribute to a more comprehensive understanding of the genetic basis of psoriasis and may pave the way for the development of personalized treatment strategies in Egyptians.

#### 5. References

1. Greb JE, Goldminz AM, Elder JT. Psoriasis. *Nat Rev Dis Primers*. 2016; 2: 16082.
2. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. *JAMA*. 2020; 323(19): 1945-60.
3. Boehncke WH, Schön MP. Psoriasis. *Lancet*. 2015; 386(9997): 983-94.
4. Menter A, Strober BE, Kaplan DH. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019; 80(4): 1029-72.
5. Mahil SK, Capon F, Barker JN. Genetics of psoriasis. *Dermatol Clin*. 2015; 33(1): 13-29.
6. Tsoi LC, Stuart PE, Tian C. Large scale meta-analysis across 3 genome-wide association studies identifies IL23R and 9 new psoriasis susceptibility loci. *Nat Genet*. 2012; 44(11): 1326-30.
7. Okada Y, Wu D, Trynka G. Genetics of rheumatoid arthritis contributes to biology and drug discovery. *Nature*. 2014; 506(7488): 376-81.
8. Stuart PE, Nair RP, Ellinghaus E. Genome-wide association analysis identifies three psoriasis susceptibility loci. *Nat Genet*. 2010; 42(11): 1000-4.
9. Nair RP, Duffin KC, Helms C. Genome-wide scan reveals association of psoriasis with IL-23 and NF- $\kappa$ B pathways. *Nat Genet*. 2009; 41(2): 199-204.
10. Elder JT. Genome-wide association studies in psoriasis. *J Invest Dermatol*. 2010; 130(7): 1813-6.
11. Dand N, Ramkumar V, Ramachandran G. The interplay of genetics and immunity in psoriasis pathogenesis. *J Autoimmun*. 2018; 94: 85-96.
12. Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. *Nat Rev Immunol*. 2014; 14(9): 585-600.
13. Di Meglio P, Di Cesare A, Laggner U. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. *PLoS One*. 2013; 8(2): e57385.
14. Capon F, Di Meglio P, Szaub J. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. *Hum Genet*. 2007; 122(2): 201-6.
15. Cho JH, Bowman C. The genetics of psoriasis and psoriatic arthritis. *Clin Chest Med*. 2010; 31(1): 87-106.
16. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. *Nat Rev Immunol*. 2009; 9(10): 679-91.
17. Chiricozzi A, Romanelli P, Volpe E, Borsellino G. IL-17 and Psoriasis. *Cytokine Growth Factor Rev*. 2018; 39-40: 32-40.
18. Ogawa K, Muromoto R, Ishiguro K. The role of CARD14 in psoriasis and other inflammatory diseases. *Int J Mol Sci*. 2018; 19(2): 365.
19. Mahil SK, Catapano F, Di Meglio P, Dand N, Ahlfors H, Carr IM. An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a

psoriasis therapeutic target. *Sci Transl Med.* 2017; 9(411).

20. Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: a comprehensive review. *J Autoimmun.* 2015; 64: 66-73.